Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
enlighten me...I've seen two different estimates in the S-4 of the exchange rate ( not reverse split ratio ) of 40 shares of MSTX to 1 of Savara and a high of 46.72 shares of MSTX for 1 of Savara. My question is why would the price rise knowing full well at the time of THE REVERSE merger you will give up at least 40 of your shares at whatever the share price is at the time for 1 of Savara. The ratio will be fixed ( stated clearly in the S4 ) so if Savara is priced at $5 and MSTX is trading for .30 per share you would pay $12 for a $5 share of Savara.
I don't understand any enthusiasm for this deal or buying into MSTX at this point.
from EU, I swim between the stocks with big crash which one of beautiful prospects ...
what a scam should see 12s here soon $mstx
Trendy, So how did you come to invest in MSTX and how did you come to the life sciences stocks? Where are you located?
I think the same , I'm in since November ... I'm ok .. j waits the informations ... before 31/03 we will a few things ..
Yes. Patience is called for. I would expect that MSTX shareholders will need to approve both the reverse merger and the reverse split just before Savara shareholders vote. But that's just my expectation and is not based on any discussion with management.
Thx .. no i m not sharolder of svra... patience :) thank you!
Trendy, Are you a holder of Savara too (as am I)? As of 8:40 ET this morning, I at least have not received anything from Savara on timing of a vote. The last materials I officially received were in the time frame of the merger announcement and that had no date. Have you received anything?
If I recall, there are under a hundred holders of Savara, so getting a vote done is not too tough. EDIT: and these are actual people and partnerships in whose name the shares are held. It's not like MSTX, where Fidelity is one holder for EVERYONE with their shares in street name at Fidelity, etc.
When is the savara shareholder approval vote ? Thx
Pray, THAT is a very interesting observation. Thank you.
What I noted was his education and background. He graduated from Dallas Theological Seminary. I have personally know hundreds of men from Dallas Theological Seminary in both business, as well as theology. Not one has ever disappointed me.
Gapping up to 60 cents would be quite welcome.
Ahall, You're quite welcome.
Pray, A 1 for 20 reverse split sounds pretty reasonable. Remember the new company needs some cushion well above the minimum SP for uplisting. Maybe 1 for 30.
Savara management had always been responsive to questions, subject to not giving out clearly non-public info. I've spoken many times with Rob Neville, even tho I am one of the smaller holders among the angel investors.
However, now that they are in this process with a public company and becoming a publicly listed company themselves, I believe they will still try to be responsive to shareholders but will need to remain more pure than Caesar's wife.
Their responsiveness and openness has, I believe, been key in their having their cooperative relationships with the CFF and FDA, among other entities.
Best of luck to you and to all longs
Baker Bros. sold their position in MSTX
Just think about that open gap till .60$ to fulfill ...
Jmo
Pattern staying true .....
Before reading your post I was figuring .25-35 before split. IMO there will be a 20/1 split. The higher the better reducing the number of shares. Then the "short squeeze is on. What little research I have done on new CEO, he will be great for company. Seems to value shareholders unlike Cully who has been complete failure. Good luck.
Thank you so much for your insights!
Rather than my throwing numbers out there, why not look at some of the articles and blogposts Leny Hettmansperger has put out over on Seeking Alpha. The most recent one I have is: http://seekingalpha.com/instablog/44479986-leny-hettmansperger/4955333-inexpensive-stock-star-portfolio-plx-63c-mstx-13c-wstl-65c-amrs-45c-xtnt-35c-cbio-50c?app=1&uprof=44&isDirectRoadblock=false
This one covers several stocks but a number of his but others focus on just MSTX. The link to his list of blogposts: http://seekingalpha.com/author/leny-hettmansperger/instablogs
That said, I think he was propounding the thesis that the stock will rise to $.30 or so before the reverse split. I sure don't know what the ratio in the r/s will be, but it will have to be high enough to support uplisting the shares.
After the R/S, he was estimating the shares would grow sharply, once MSTX management is let go and the company is renamed Savara. They have two phase 2 studies ongoing on different drugs, a great relationship with the CF Foundation (which has provided non-dilutive funding) and a coorperative working relationship with the FDA.
I came into this as a long-time Savara shareholder (private as of now) with confidence in Savara management.
What kind of premium price we potentially looking at?
What's up, you ask? Reverse merger into a private entity, Savara Pharma, with a dynamic management. The merged company will trade as Savara, and there should be a nice merger premium at the current price.
Good to hold on to those 100k shares. Hope Leny's predictions of a sharp merger premium are accurate.
having read the numbers of the S4 I would ask Culley: why Savara?
Wouldn't it be better a cardiological Company? Maybe with a P3 close to the end, or with devices for HF on the market?
Yep, .158 and then plunge.
Doesn't matter, I buy 75,000 @ .142 in the dip, Ha!
If we've reached .158 it will go back one way or another. Just shaking the tree here.
And no trace of this "trade" @ .118 on both sites... weird
GL
Got it. I have less than 10K shares so only a small position. Might or might not hold through the merger. Not sure.
What price do u think this opens at
Click on news above its there.......
I see no record of insider buys there or anywhere else I looked.
Go to finviz you can find MSTX news and insider buys
If you want to see insider buys reported or news on a stick. Go to finviz and type in MSTX
Uh, NO. That's why I asked!
Do you know what you are talking about?
It's a possibility, I do agree.
This friday, I sold 80,000 shares @ 0.147 just before the close.
I stay with 100,000 in reserve for the spike eventually...
GL
Reverse split of undetermined amount is part of the plan ?
.15 on tape AH level2. have a great weekend!!
Loaded .1465, not the best intraday entry but I like the chart going into next week. Anyone know what's up here fundamentally?
7 is right above 4 on my keyboard numeric pad. Someone probably just had a "fat" finger putting in the order.
It would be nice if those of you that says things like this would post a chart showing your guesses or at least some company news or PR giving your guesses some firm ground to stand on. Come on, prove your thoughts!!!
My own DD is already done.
This is big manipulating since that single trade made @ 0.17
Hang on strongly, it will probably more shaked till 14th...
GL
(own 180,000 shares)
People need to seriously chill on this. We know news has to be out by the 14th. So just wait 4 more trading days, Jesus Christ
Where come that trade @ 0.17 from ?
9:30 102793 0.17$ NSD
It false completely the chart!!!
There's nothing between 0.17 and 0.145 today!!!
I own 180,000 shares @ 0.131 and 0.128 bought on friday.
GLTA
Good Volume this AM. .15 is the key for now. GL
Past pattern is slight increase on Friday looking for Monday news. After Monday a 4-6% drop on Tues, Weds, Thursday before increase again on Friday.
Seems as a lame duck until merger or RS. Both great IMO.
Followers
|
304
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
15766
|
Created
|
08/30/05
|
Type
|
Free
|
Moderators |
We are a publicly traded biopharmaceutical company headquartered in San Diego, California.
We are leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop vepoloxamer, our lead product candidate, for serious or life-threatening diseases with significant unmet needs.
To learn more about our company, please see our Letter from the CEO.
http://www.masttherapeutics.com/investors/
Purpose
Condition | Intervention | Phase |
---|---|---|
Vaso-occlusive Crisis Sickle Cell Disease | Drug: Saline Drug: MST-188 | Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
Official Title: | Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis |
Estimated Enrollment: | 388 |
Study Start Date: | May 2013 |
Estimated Primary Completion Date: | December 2015 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: MST-188 MST-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours. | Drug: MST-188 Other Name: vepoloxamer |
Placebo Comparator: Saline Saline administered as a continuous infusion for up to 49 hours | Drug: Saline |
Ages Eligible for Study: | 4 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Mast Therapeutics CT.gov Call Center | 1-888-965-1238 |
Study Director: | Edwin L. Parsley, D.O. | Mast Therapeutics, Inc. |
Responsible Party: | Mast Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT01737814 History of Changes |
Other Study ID Numbers: | MST-188-01 |
Study First Received: | November 27, 2012 |
Last Updated: | September 24, 2015 |
Health Authority: | United States: Food and Drug Administration Belgium: Federal Agency for Medicines and Health Products, FAMHP Brazil: National Committee of Ethics in Research Dominican Republic: Consejo Nacional de Bioetica en Salud Jordan: Jordanian Food and Drug Administration Lebanon: Institutional Review Board Oman: Academic Accreditation Authority Panama: Ministry of Health Spain: Ministerio de Sanidad, Servicios Sociales e Igualdad Saudi Arabia: Saudi Food and Drug Administration Turkey: Drug and Medical Device Institution Jamaica: Ministry of Health |
sickle cell disease vaso-occlusive crisis |
Anemia, Sickle Cell Anemia Anemia, Hemolytic Anemia, Hemolytic, Congenital | Genetic Diseases, Inborn Hematologic Diseases Hemoglobinopathies |
MST-188 (purified poloxamer 188) is an investigational agent that has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. We initially are developing MST-188 as a treatment for complications arising from sickle cell disease.
AIR001 is a sodium nitrite solution for intermittent inhalation via nebulizer. Nitrite is a direct vasodilator and can be recycled in vivo to form nitric oxide (NO) independent of the classical NO synthase (NOS) pathway. Nitrite mediated NO formation has several beneficial effects, including dilation of blood vessels and reduction of inflammation and undesirable cell growth. Generation of NO from sodium nitrite is not dependent upon endothelial function and is enhanced in the setting of tissue hypoxia and acidosis, conditions in which NOS activity typically is depressed. In early clinical studies, AIR001 demonstrated positive hemodynamic effects with reductions observed in right atrial pressure and pulmonary capillary wedge pressure, as well as improvements in mean pulmonary artery pressures and cardiac output.
We are developing AIR001 for treatment of heart failure with preserved ejection fraction (HFpEF), a condition that affects millions in the U.S. and for which no proven therapeutic agent is available. Numerous lines of evidence suggest that HFpEF is a disease of NO deficiency. We are supporting two institution-sponsored Phase 2a studies in patients with HFpEF to evaluate acute hemodynamic effects of AIR001 and to evaluate its acute effects versus placebo on submaximal oxygen consumption and exercise hemodynamics.
AIR001 Inhalation Solution is sodium nitrite formulated with a phosphate buffer into an inhalation solution. Nitrite is a physiological signaling molecule with roles in intravascular endocrine nitric oxide (NO) production, hypoxic vasodilation, signaling, and cytoprotection after ischemia-reperfusion. Nitrite serves as the largest physiologic reservoir of NO and can be converted to NO independent of NO synthase (NOS) activity.
In experimental models, nitrite use demonstrated improved remodeling both in the pulmonary vasculature and right ventricle. Hemodynamic effects include venodilation with reductions in right atrial pressures, pulmonary and systemic vasodilation with reductions in pulmonary vascular resistance and left atrial pressures, and improved cardiac relaxation. In addition, recent clinical and nonclinical studies have demonstrated that nitrite can stimulate mitochondrial biogenesis and mitochondrial fusion and decrease mitochondrial oxygen consumption through a mechanism distinct from that of NO, which may have utility in treating heart failure.
We obtained the AIR001 program through our acquisition of Aires Pharmaceuticals, Inc. in February 2014. Prior to the acquisition, AIR001 had been tested in more than 120 healthy volunteers and patients with various forms of pulmonary hypertension in three Phase 1 studies and in one Phase 2 study in patients with pulmonary arterial hypertension. While the Phase 2 study was prematurely terminated due to Aires’ capital constraints prior to the acquisition, preliminary data from the study are positive, showing improvements in hemodynamic parameters and in exercise capacity from baseline. There were no treatment-related serious adverse events and methemoglobin levels remained normal (< 1.5%), which distinguishes AIR001 from safety concerns associated with intravenously-administered nitrite.
Data from these early clinical studies support continued clinical development of AIR001. Given the observed hemodynamic improvements of decreased right arterial pressure, decreased pulmonary capillary wedge (or left atrial pressure), as well as improvements in pulmonary vascular resistance and cardiac lusitropic effects, AIR001 may benefit patients with exercise impairment due to heart failure with preserved ejection fraction (HFpEF), for whom these are all desirable effects.
Hemodynamic improvements, improvements in pulmonary artery pressures, and cardiac lusitropic effects observed in earlier studies of AIR001 support AIR001’s potential to benefit patients with heart failure with preserved ejection fraction (HFpEF). We currently are pursuing clinical development of AIR001 for that patient population.
Event Timing
Initiate tQT/QTc Study Completed
Secure Orphan Designation for MST-188 for SCD in EU Completed
Activate First Site in Phase 3 Study Completed
File New Patent Applications Completed
Dose First Subject in Phase 3 Study Completed
Report data from tQT/QTc Study Q3 Completed and Primary Endpoints Met
Request Orphan Designation for MST-188 for ALI in U.S. Q3 Completed and Designation Granted By FDA
Initiate Nonclinical Proof-of-Concept Study in Heart Failure Q3 Completed and POC Data to be released Q1 '14
2014 Activities
Event Timing
Present Data From Nonclinical Proof-of-Concept Study In Heart Failure Q1 '14 Data Released 01/06/14'Showed Significant Statistical Improvement"
Initiate Phase 2 Study in ALI Q1 '14 Initiated
Outcome of review of application for Unique Name Designation For Purified Poloxamer 188 From U.S. Adopted Names Counsel Q1 '14 Granted and Named VEPOLOXAMER
Open First Ex-U.S. Clinical Sites in Phase 3 Trial Q1 '14. Initiated and On Schedule
Submit Abstract with Heart Failure Study Biomarker Data to Major Medical Conference Q2 '14
Request Orphan Designation for ALI in EU Q2 '14 Application Submitted
Initiate Nonclinical POC Study in Stroke Q2 '14 Study Initiated
Initiate EPIC Sub-Study Q2 '14 Initiated On Schedule 06/14/14
Report Results from Phase 2 Study of AIR001 in PAH Q3 '14 Positive Top line Data released 9/8/14
Initiate study with Dept of Defense: MST-188 Resuscitation from major trauma '14 CRADA with US Military Initiated Q3 '14
Receive protocol from FDA for Phase 2 Heart Failure Study Q4'14 FDA Approves Heart Failure Study 12/9/14
2015 Event Schedule
Initiate dosing Phase2a study in AIR001 Q1 '15. INITIATED 2/4/15
Nonclinical Study EMBOLIC STROKE Data Q1 '15: POSITIVE DATA RELEASED 2/11/15
Report nonclinical data for repeat dose on Vepoloxamer in Heart Failure Q1 '15 POSITIVE DATA RELEASE 03/02/15
Phase 2 Study HEART FAILURE Initiate Enrollment Q2 '15 INITIATED 3/23/15
EPIC EXTENSION STUDY (Repeat Exposure) Initiate Enrollment 1st Half '15 INITIATED 5/26/15
Phase 2a Study of AIR001 (WHO GROUP 2) in HFpEF Preliminary Data 2nd Half '15
Phase 2 Study Heart Failure Interim Safety Analysis 2nd Half '15
EPIC STUDY COMPLETE ENROLLMENT Q4 '15
2016 EVENTS
EPIC Top Line Data Q1 2016
Video of Management of Mast Therapeutics $MSTX speaking about MST-188 for Sickle Cell Disease ,orphan drug
http://www.youtube.com/watch?v=eI7inPOiyZM&feature=youtu.be
http://www.masttherapeutics.com/wp-content/uploads/2013/04/EPIC-An-Ongoing-Pivotal-Phase-3-Study-in-Patients-with-Sickle-Cell-Disease-Aug-21-2013.
Filing Company | Date of Filing | Total Reported Shares Owned | Shares Reported on 13F | |
---|---|---|---|---|
Baker Bros LLC | 12/31/14 | 4,774,434 | 4,774,434 | |
BVF Inc. | 3/31/15 | 7,241,600 | 7,241,600! | |
SC 13G | FRANKLIN RESOURCES INC | 02/04/15 | 11,946,100 | 11,946,100 |
Reported via | Event Date | Name | Ticker | Shares * | Change | % of Portfolio |
---|---|---|---|---|---|---|
13F MPM Asset Management | MSTX | 2,551,851 | ||||
13F Vanguard Group | MSTX | 3,382,483 |
http://stockcharts.com/h-sc/ui?s=MSTX&p=D&b=2&g=0&id=p32395513381
http://stockcharts.com/h-sc/ui?s=MSTX&p=D&b=9&g=0&id=p36778398928
http://stockcharts.com/freecharts/gallery.html?MSTX
P: 858-552-0866 F: 858-552-0876
General Inquiries
info@mastthera.com
Investor Relations Contact
ir@mastthera.com
Business Development Contact
busdev@mastthera.com
Careers Contact
hr@mastthera.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |